Company news

Guardant Health, Inc. news in 2022

Guardant Health, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Guardant Health to Participate in the 41st Annual J.P. Morgan Healthcare Conference

December 27, 2022

Guardant Health and Susan G. Komen® Partner to Develop Clinical Studies to Identify Early-Stage Breast Cancer Patients Who May Benefit From Additional Monitoring or Therapy

December 20, 2022

Guardant Health announces positive results from pivotal ECLIPSE study evaluating a blood test for the detection of colorectal cancer

December 14, 2022

Guardant Health Announces Collaboration With AstraZeneca to Develop Companion Diagnostic to Identify Patients With ESR1-mutated Metastatic Breast Cancer

December 7, 2022

Guardant Health to Showcase New Data at San Antonio Breast Cancer Symposium 2022 Demonstrating Utility of Its Blood Tests for Advanced-stage Breast Cancer Patients

November 30, 2022

Guardant Health Reports Third Quarter 2022 Financial Results

November 2, 2022

Guardant Health to Report Third Quarter 2022 Financial Results on November 3, 2022

October 9, 2022

Guardant Health Introduces GuardantINFINITY™ Smart Liquid Biopsy for Research Use to Help Bring New Cancer Therapies to Patients Sooner

September 8, 2022

Guardant Health to showcase new data at ESMO 2022 demonstrating utility of its portfolio of blood tests for advanced-stage cancer patients

September 5, 2022

Guardant Health Expands Strategic Collaboration With Merck KGaA, Darmstadt, Germany, to Help Accelerate Development of Precision Oncology Therapeutics

August 30, 2022

Guardant Health to Participate in the Morgan Stanley Global Healthcare Conference

August 28, 2022

Guardant Health Expands Use of Guardant Reveal™ Liquid Biopsy Test for Residual Disease Detection and Recurrence Monitoring to Include Early-Stage Breast and Lung Cancers

August 14, 2022

Guardant Health Receives FDA Approval for Guardant360® CDx as Companion Diagnostic for Daiichi Sankyo and AstraZeneca’s ENHERTU® for Treatment of NSCLC Patients With Activating HER2 Mutations

August 11, 2022

Guardant Health Announces New Data from its Portfolio of Blood Tests and GuardantINFORM™ Real-World Clinical-Genomic Platform at IASLC 2022 World Conference on Lung Cancer

August 4, 2022

Guardant Health Reports Second Quarter 2022 Financial Results

August 3, 2022

Guardant Health Receives Medicare Coverage for Guardant Reveal™ Test

August 1, 2022

Guardant Health to Report Second Quarter 2022 Financial Results on August 4, 2022

July 12, 2022

Steve E. Krognes Joins Guardant Health Board of Directors

July 6, 2022

Guardant Health and Adicon announce strategic partnership to offer comprehensive genomic profiling tests to accelerate development of new cancer therapies in China

July 5, 2022

Guardant Health Completes Purchase of Guardant Health AMEA Joint Venture

June 12, 2022

Guardant Health Presents New Data Showing Blood Test Accuracy in Detecting Colorectal Cancer in First-of-its Kind Prospective Study at Digestive Disease Week 2022

May 20, 2022

Guardant Health Reports First Quarter 2022 Financial Results

May 4, 2022

Guardant Health Announces Shield™ Blood Test Available in US to Detect Early Signs of Colorectal Cancer in Average-Risk Adults

May 1, 2022

Guardant Health to Report First Quarter Financial Results on May 5, 2022

April 12, 2022

Guardant Health Presents New Data Showing Blood Test Highly Accurate in Detecting Multiple Cancers at the American Association for Cancer Research Annual Meeting

April 10, 2022

Guardant Health Announces Partnership with Epic to Streamline Access to Company’s Broad Portfolio of Cancer Tests

April 3, 2022

Guardant Health Receives Regulatory Approval for Guardant360® CDx in Japan

March 13, 2022

Guardant Health Receives Medicare Coverage for Guardant360 TissueNext™ Test

March 7, 2022

Guardant Health Reports Fourth Quarter 2021 Financial Results and Provides 2022 Outlook

February 22, 2022

Guardant Health Enrolls First Patient in SHIELD LUNG Study to Evaluate Accuracy of Its Blood Test to Detect Lung Cancer in High-Risk Adults

January 17, 2022

Calls in 2022

Decks in 2022